Health1 min read

STAT+: Early results for Alterome’s KRAS drug for pancreas, lung and colon cancer arrive

By · Via STAT Health · Published by Everything Blog

In short

Initial trial data have become available regarding an experimental cancer candidate being advanced by Alterome. The therapeutic agent is designed to specifically inhibit KRAS-driven disease processes across several tumor types. Researchers are currently tracking its effects in patients suffering from pancreas, lung, and colon cancers. Continued analysis of these findings will determine the candidate's trajectory toward further clinical development.

Key points

  • Early clinical findings provide critical initial data regarding the performance of Altero…: Early clinical findings provide critical initial data regarding the performance of Alterome's novel KRAS inhibitor.
  • The targeted therapeutic intervention addresses three major oncology settings encompassin…: The targeted therapeutic intervention addresses three major oncology settings encompassing pancreas, lung, and colon cancers.
  • Subsequent updates will rely on how these preliminary findings establish the compound's b…: Subsequent updates will rely on how these preliminary findings establish the compound's broader efficacy and safety.

Sources checked by our analysis pipeline: 1

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today’s newsletter has a bit of everything: peptides, China, Congress, and cancer drugs. Biotech in 2026 is never dull.

Hims and Noom take peptides further into mainstream

Hims & Hers and Noom are getting into the synthetic peptide business, bringing treatments marketed for muscle maintenance, intimacy, and longevity to a much larger audience — often with little evidence to support those uses. Both are already offering compounded drugs and eyeing BPC-157 and TB-500, two of six unapproved peptides covered by a new HHS policy easing enforcement against compounding pharmacies, STAT’s Sarah Todd and Katie Palmer write.

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Health